Glivecbehandling inducerer et hurtigt respons hos nydiagnosticerede pædiatriske CML- patienter med en CHR hos 78% efter 8 ugers behandling.
Glivec treatment induces a rapid response in newly diagnosed paediatric CML patients with a CHR of 78% after 8 weeks of therapy.